# Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors

> **NCT07589530** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing Biotech** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Metastatic Solid Tumors
- TROP2-Expressing Solid Tumors

## Interventions

- **BIOLOGICAL:** EB-NK-301
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT07589530
- **Lead sponsor:** Beijing Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-02
- **Primary completion:** 2027-02-14
- **Final completion:** 2028-03-17
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07589530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07589530, "Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT07589530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*